HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

New Approaches in Tumor Necrosis Factor Antagonism for the Treatment of Psoriatic Arthritis: Certolizumab Pegol.

Abstract
The pathogenesis of psoriatic arthritis (PsA) is still under discussion but great advances have been made in the last 2 decades that confirm the central role of tumor necrosis factor-α (TNF-α) in its inflammatory milieu. New therapeutic approaches have been proposed, and new molecules with anti-TNF-α activity have been chemically altered to improve their pharmacological properties. Certolizumab pegol (CZP) is a PEGylated Fc-free anti-TNF that has been shown clinically to be effective in the treatment of rheumatoid arthritis (RA), skin psoriasis, and PsA. This article summarizes available data on its clinical efficacy and safety profile in the treatment of patients with PsA.
AuthorsAlberto Cauli, Matteo Piga, Ennio Lubrano, Antonio Marchesoni, Alberto Floris, Alessandro Mathieu
JournalThe Journal of rheumatology. Supplement (J Rheumatol Suppl) Vol. 93 Pg. 70-2 (Nov 2015) ISSN: 0380-0903 [Print] Canada
PMID26523062 (Publication Type: Journal Article, Review)
Chemical References
  • Antirheumatic Agents
  • Biological Products
  • Tumor Necrosis Factor-alpha
  • Certolizumab Pegol
Topics
  • Antirheumatic Agents (adverse effects, therapeutic use)
  • Arthritis, Psoriatic (diagnosis, drug therapy, immunology)
  • Biological Products (adverse effects, therapeutic use)
  • Certolizumab Pegol (adverse effects, therapeutic use)
  • Humans
  • Treatment Outcome
  • Tumor Necrosis Factor-alpha (antagonists & inhibitors, immunology)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: